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Accurate diagnosis of TTC has substantial prognostic implications in an ICU, given its increased mortality risk and association with life-threatening complications. This report will discuss diagnostic modalities that can be useful in accurately differentiating TTC from ACS, and also briefly discuss the prevention and management of TTC in an ICU.
Takotsubo Cardiomyopathy is more prevalent in an ICU than initially thought. A recent study in South Korea performed serial TTE on 92 ICU patients and identified the syndrome in 28%. 2 TTC in an ICU is also associated with a higher mortality rate. It can potentially exacerbate the underlying medical condition of critically ill patients and worsen prognosis and outcome. Given the putative pathogenic mechanism of catecholaminemediated damage, it is imperative to minimize physical stress and administration of inotropic medications as much as possible in severely critical TTC patients.
Who to suspect? Takotsubo is typically reported in postmenopausal women and associated with pheochromocytoma and intracranial hemorrhage. However, any ICU patient in critical condition who possibly received catecholamine-based inotropic medication is at risk of developing TTC. Typical clinical findings including angina, dyspnea, palpitations, hemodynamic deterioration, hypoxia, or dynamic ECG changes should necessitate immediate evaluation for TTC by cardiac biomarkers and BNP, urgent TTE, and serial ECGs.
How to differentiate TTC from ACS accurately? Due to the increased amount of ICU patients with Takotsubo Cardiomyopathy, it is imperative to differentiate TTC from ACS accurately because managements differ substantially. In early stages of TTC, LV dysfunction is disproportionate to the degree of elevation in cardiac enzymes, as opposed to ACS, which has higher levels of troponin. Cardiac enzymes are accurately measured by the TEFR index, which is the ratio between peak troponin and LVEF. TEFR value ≤ 60 suggests TTC over ACS. 3 Takotsubo is also uniquely associated with marked release of BNP and N-terminal pro-BNP. 4 Transthoracic echocardiogram shows characteristic wall motion abnormalities of transient hypokinesis/akinesis/dyskinesis of left and/or right ventricular segments, and decreased ejection fraction. A wall motion index can be used to more accurately calculate the extent of regional hypokinesis. Although ECG changes are generally not reliable, low QRS voltage and attenuation of QRS complexes in serial ECGs have been shown to be highly prevalent and specific to TTC. 5 Other nonspecific ECG changes include ST-segment elevation, diffuse T-wave inversion, and QTc DOI: 10.17987/icfj.v5i0.214 prolongation. Coronary angiography (CAG) is the preferred diagnostic modality to rule out ACS, but select ICU patients particularly vulnerable to complications may require more accurate diagnosis and efficient monitoring of complications. Cardiovascular magnetic imaging (CMR) emerges as an invaluable noninvasive imaging tool to definitively rule out ACS and other cardiomyopathies, precisely quantify ventricular dysfunction, and accurately visualize intraventricular thrombi and myocardial injury (Table 1 ).
How to manage such patients? Management of critical Takotsubo patients involves judicious monitoring of TTCassociated complications, treatment of underlying illnesses, and avoidance of catecholamine medications. Shock is the most common complication of TTC, 6 and understanding its multifactorial mechanism is essential to establish optimal management. TTC-related shock is uniquely associated with a mild elevation in pulmonary capillary wedge pressure. 7 Right heart catheterization studies are recommended to analyze the multifactorial mechanisms of TTC-related shock. Patients should also be monitored for arrhythmias by serial ECGs until QTc duration normalizes. 8 Currently, no randomized control trials have been performed to establish therapeutic guidelines for TTC. Administration of inotropic agents should theoretically be avoided due to potentially aggravating effects of increased cardiac workload, arrhythmias, direct myocardial toxicity, and outflow obstruction. Levosimendan, a calcium sensitizer non-catecholamine inotrope, has emerged as a favorable therapeutic agent in cardiogenic shock. Anticoagulation therapy is recommended in all TTC patients until resolution of dyskinesia to prevent LV thrombus. Also, a recent meta-analysis found that ACE inhibitors, and not beta-blockers, reduce risk of recurrence of TTC 9 (Table 2) .
Overall, it is important that the medical community changes its mindset to recognize Takotsubo Cardiomyopathy as a diagnosis in itself, and not a diagnosis of exclusion. It is essential to appreciate that Takotsubo is not merely a primary condition, but can occur as a comorbidity of critical illness. This report supports the expanded use of focused cardiac ultrasound throughout the clinical course of ICU patients. Lastly, in a time of minimizing invasive diagnostic procedures and performing evidence-based medicine, this manuscript recommends increased utilization of cardiac magnetic imaging as a diagnostic modality for Takotsubo patients in an ICU, counteracting costs of missed diagnosis or overlooked complication.
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The author declares no conflicts of interest. Anticoagulation until wall motion abnormalities resolve.
Monitor patients for arrhythmias until QTc interval normalizes.
Follow-up echocardiography.
Shock
Right heart catheterization study.
Avoid use of catecholamine based inotropic medications.
Extracorporeal membrane oxygenation (ECMO) or left ventricular assist device in refractory cases.
Ventricular arrhythmia
Magnesium replacement.
Stop medications that prolong QTc duration.
Mural thrombus
Oral anticoagulation for three months or until thrombus resolves.
LVOT obstruction
Avoid use of inotropic agents and medications that increase obstruction such as digoxin. 
